

Stefano Iacobelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11657434/publications.pdf>

Version: 2024-02-01

96
papers

5,831
citations

101543

36
h-index

74163

75
g-index

96
all docs

96
docs citations

96
times ranked

7116
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Gal-3BP plasma levels in hospitalized patients infected with SARS-CoV-2. Clinical and Experimental Medicine, 2022, , 1.	3.6	2
2	Gal-3BP in Viral Infections: An Emerging Role in Severe Acute Respiratory Syndrome Coronavirus 2. International Journal of Molecular Sciences, 2022, 23, 7314.	4.1	3
3	Improvement of urinary tract symptoms and quality of life in benign prostate hyperplasia patients associated with consumption of a newly developed whole tomato-based food supplement: a phase II prospective, randomized double-blinded, placebo-controlled study. Journal of Translational Medicine, 2021, 19, 24.	4.4	10
4	EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors. Pharmaceutics, 2021, 13, 483.	4.5	7
5	Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target. Journal of Translational Medicine, 2021, 19, 405.	4.4	50
6	Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma. Cancers, 2020, 12, 2989.	3.7	16
7	Antibody-Drug Conjugates: The New Frontier of Chemotherapy. International Journal of Molecular Sciences, 2020, 21, 5510.	4.1	83
8	Surface-enhanced Raman scattering (SERS)-based immunosystem for ultrasensitive detection of the 90K biomarker. Analytical and Bioanalytical Chemistry, 2020, 412, 7659-7667.	3.7	11
9	HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies. EMBO Molecular Medicine, 2020, 12, e11498.	6.9	30
10	Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates. Journal of Controlled Release, 2019, 294, 176-184.	9.9	30
11	EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. Journal of Controlled Release, 2018, 277, 48-56.	9.9	23
12	Efficacy and Safety of Lycoprozen®, a Novel Tomato-Based Food Supplement in Patients with Benign Prostatic Hyperplasia. International Journal of Nutrition, 2018, 3, 1-5.	0.7	3
13	Functional and prognostic significance of the genomic amplification of frizzled 6 (<i>FZD6</i>) in breast cancer. Journal of Pathology, 2017, 241, 350-361.	4.5	66
14	Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma. Oncotarget, 2017, 8, 60368-60377.	1.8	13
15	EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma. Oncotarget, 2017, 8, 95412-95424.	1.8	22
16	Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants. Oncology Letters, 2016, 12, 453-458.	1.8	1
17	Prognostic relevance of LGALS3BP in human colorectal carcinoma. Journal of Translational Medicine, 2015, 13, 248.	4.4	26
18	Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget, 2015, 6, 3932-3946.	1.8	60

#	ARTICLE	IF	CITATIONS
19	ErbB-3 activation by NRG-1 ^{Î²} sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs). <i>Oncotarget</i> , 2015, 6, 16902-16911.	1.8	29
20	Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti-“Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 916-925.	4.1	21
21	Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 1575-1582.	1.5	11
22	Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1229-1240.	2.5	8
23	LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. <i>Journal of Molecular Medicine</i> , 2013, 91, 83-94.	3.9	63
24	Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 269-280.	2.5	19
25	EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. <i>Translational Oncology</i> , 2013, 6, 676-IN9.	3.7	26
26	Overexpression of activated phospholipase C ^{Î³1} is a risk factor for distant metastases in T1â€T2, N0 breast cancer patients undergoing adjuvant chemotherapy. <i>International Journal of Cancer</i> , 2013, 132, 1022-1031.	5.1	41
27	Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer. <i>Disease Markers</i> , 2013, 35, 747-752.	1.3	6
28	Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. <i>Cancer</i> , 2013, 119, 2564-2573.	4.1	40
29	An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis. <i>Biomarkers in Cancer</i> , 2013, 5, BIC.S13236.	3.6	18
30	Prediction of overall survival through circadian restâ€activity monitoring during chemotherapy for metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2012, 131, 2684-2692.	5.1	102
31	Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 221-229.	2.5	30
32	Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 464-464.	1.6	6
33	Prediction of Survival by Neutropenia According To Delivery Schedule of Oxaliplatinâ€5-Fluorouracilâ€Leucovorin for Metastatic Colorectal Cancer in a Randomized International Trial (EORTC 05963). <i>Chronobiology International</i> , 2011, 28, 586-600.	2.0	37
34	Fucans, but Not Fucomannoglucuronans, Determine the Biological Activities of Sulfated Polysaccharides from <i>Laminaria saccharina</i> Brown Seaweed. <i>PLoS ONE</i> , 2011, 6, e17283.	2.5	104
35	Sentinel Node and Bone Marrow Micrometastases and Nanometastases. <i>Current Breast Cancer Reports</i> , 2010, 2, 96-106.	1.0	4
36	Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactosideâ€binding soluble 3 binding protein (LGALS3BP). <i>International Journal of Cancer</i> , 2010, 126, 41-52.	5.1	31

#	ARTICLE	IF	CITATIONS
37	A Dietary Tomato Supplement Prevents Prostate Cancer in TRAMP Mice. <i>Cancer Prevention Research</i> , 2010, 3, 1284-1291.	1.5	42
38	Circadian Rhythm in Rest and Activity: A Biological Correlate of Quality of Life and a Predictor of Survival in Patients with Metastatic Colorectal Cancer. <i>Cancer Research</i> , 2009, 69, 4700-4707.	0.9	195
39	Liver Circadian Clock, a Pharmacologic Target of Cyclin-Dependent Kinase Inhibitor Seliciclib. <i>Chronobiology International</i> , 2009, 26, 1169-1188.	2.0	0
40	High expression of 90K (Mac-2BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. <i>International Journal of Cancer</i> , 2009, 124, 333-338.	5.1	36
41	LIVER CIRCADIAN CLOCK, A PHARMACOLOGIC TARGET OF CYCLIN-DEPENDENT KINASE INHIBITOR SELICICLIB. <i>Chronobiology International</i> , 2009, 26, 1169-1188.	2.0	35
42	Phospholipase C β 1 Is Required for Metastasis Development and Progression. <i>Cancer Research</i> , 2008, 68, 10187-10196.	0.9	135
43	Upstream Stimulatory Factor Regulates Constitutive Expression and Hormonal Suppression of the 90K (Mac-2BP) Protein. <i>Endocrinology</i> , 2007, 148, 3507-3517.	2.8	8
44	Relief of Symptoms After Gefitinib Is Associated With Improvement of Rest/Activity Rhythm in Advanced Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, e17-e19.	1.6	19
45	A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. <i>Glycobiology</i> , 2007, 17, 541-552.	2.5	844
46	Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. <i>Glycobiology</i> , 2006, 16, 210-220.	2.5	114
47	PTP-PEST phosphatase variations in human cancer. <i>Cancer Genetics and Cytogenetics</i> , 2006, 170, 48-53.	1.0	36
48	Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 3562-3569.	1.6	200
49	Improved Tumor Control through Circadian Clock Induction by Seliciclib, a Cyclin-Dependent Kinase Inhibitor. <i>Cancer Research</i> , 2006, 66, 10720-10728.	0.9	109
50	Axillary Lymph Node Nanometastases Are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2006, 12, 6696-6701.	7.0	71
51	Elevated Serum Cytokines Correlated with Altered Behavior, Serum Cortisol Rhythm, and Dampened 24-Hour Rest-Activity Patterns in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 1757-1764.	7.0	231
52	Effects of Light and Food Schedules on Liver and Tumor Molecular Clocks in Mice. <i>Journal of the National Cancer Institute</i> , 2005, 97, 507-517.	6.3	188
53	Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects. <i>Cancer Research</i> , 2005, 65, 8339-8349.	0.9	126
54	The 90K Protein Increases Major Histocompatibility Complex Class I Expression and Is Regulated by Hormones, β -Interferon, and Double-Strand Polynucleotides. <i>Endocrinology</i> , 2004, 145, 4728-4736.	2.8	23

#	ARTICLE	IF	CITATIONS
55	Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. <i>Oncogene</i> , 2004, 23, 1754-1765.	5.9	89
56	Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. <i>Cancer</i> , 2004, 101, 1609-1615.	4.1	95
57	Role of 90K protein in asthma and TH2-type cytokine expression. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 93, 485-492.	1.0	30
58	Lack of Expression of Galectin-3 Is Associated With a Poor Outcome in Node-Negative Patients With Laryngeal Squamous-Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3850-3856.	1.6	42
59	Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?. <i>Trends in Immunology</i> , 2002, 23, 313-320.	6.8	493
60	Expression of the 90K Tumor-Associated Protein in Benign and Malignant Melanocytic Lesions. <i>Journal of Investigative Dermatology</i> , 2002, 119, 187-190.	0.7	16
61	The mechanism involved in the regulation of phospholipase C β 1 activity in cell migration. <i>Oncogene</i> , 2002, 21, 6520-6529.	5.9	103
62	90K (Mac-2 BP) and galectins in tumor progression and metastasis. <i>Glycoconjugate Journal</i> , 2002, 19, 551-556.	2.7	148
63	Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. <i>Cancer Research</i> , 2002, 62, 840-7.	0.9	207
64	Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. <i>Cancer Research</i> , 2002, 62, 2535-9.	0.9	88
65	Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. <i>International Journal of Cancer</i> , 2001, 91, 167-172.	5.1	18
66	PARP co-activates B-MYB through enhanced phosphorylation at cyclin/cdk2 sites. <i>Oncogene</i> , 2001, 20, 8167-8174.	5.9	27
67	Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. <i>International Journal of Cancer</i> , 2001, 91, 167-172.	5.1	95
68	Lack of mother-to-child HIV-1 transmission is associated with elevated serum levels of 90 K immune modulatory protein. <i>Aids</i> , 2000, 14, F41-F45.	2.2	7
69	Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. <i>International Journal of Cancer</i> , 2000, 85, 545-554.	5.1	194
70	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. <i>Blood</i> , 2000, 96, 3282-3285.	1.4	39
71	Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. <i>FEBS Letters</i> , 2000, 473, 311-315.	2.8	131
72	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. <i>Blood</i> , 2000, 96, 3282-3285.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Isolation and Functional Characterization of the Human 90K Promoter. <i>Genomics</i> , 1999, 57, 268-278.	2.9	14
74	90K (Mac-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. , 1998, 79, 23-26.		29
75	Expression of the 90K Immunostimulator Gene Is Controlled by a Promoter with Unique Features. <i>Journal of Biological Chemistry</i> , 1997, 272, 3674-3682.	3.4	12
76	Identification of the Tumor Antigen 90K Domains Recognized by Monoclonal Antibodies SP2 and L3 and Preparation and Characterization of Novel Anti-90K Monoclonal Antibodies. <i>Biochemical and Biophysical Research Communications</i> , 1997, 232, 367-372.	2.1	16
77	Prognostic Value of a Novel Interferon-inducible 90K Tumor Antigen. <i>Annals of the New York Academy of Sciences</i> , 1996, 784, 288-293.	3.8	8
78	The Immune Stimulatory Protein 90K Increases Major Histocompatibility Complex Class I Expression in a Human Breast Cancer Cell Line. <i>Biochemical and Biophysical Research Communications</i> , 1996, 225, 617-620.	2.1	26
79	Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to α -interferon therapy in chronic HCV hepatitis patients. <i>Journal of Hepatology</i> , 1996, 25, 212-217.	3.7	88
80	Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. , 1996, 68, 34-38.		34
81	The 90K Tumor-Associated Antigen and Clinical Progression in Human Immunodeficiency Virus Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1995, 10, 450-456.	0.3	16
82	Effects of type-I and -II interferons on 90K antigen expression in ovarian carcinoma cells. <i>International Journal of Cancer</i> , 1994, 59, 808-813.	5.1	23
83	A 90-kDa Protein Serum Marker for the Prediction of Progression to AIDS in a Cohort of HIV-1+Homosexual Men. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 811-816.	1.1	31
84	Recombinant alpha-2b-interferon dynamic test as a potential tool in predicting disease status during second look in ovarian cancer. A preliminary report. <i>Cancer</i> , 1991, 68, 2582-2585.	4.1	5
85	Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies. <i>Cancer</i> , 1990, 65, 1325-1328.	4.1	8
86	Hormone receptor status in human endometrial adenocarcinoma. <i>Cancer</i> , 1989, 64, 2572-2578.	4.1	12
87	Effects of antiestrogen and progestin on immune functions in breast cancer patients. <i>Cancer</i> , 1988, 61, 2214-2218.	4.1	19
88	Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. <i>Breast Cancer Research and Treatment</i> , 1988, 11, 19-30.	2.5	52
89	Antiproliferative effects of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 1988, 114, 306-308.	2.5	56
90	Growth promoting influences of estradiol, epidermal growth factor, and insulin on human breast cancer: Evidence for differential mechanism of action on tumor cells in vitro. <i>Breast Cancer Research and Treatment</i> , 1985, 6, 255-256.	2.5	5

#	ARTICLE	IF	CITATIONS
91	Steroid Hormone Receptors in Endocrine-Related Tumors. , 1984, , 161-193.		1
92	Two new estrogen-supersensitive variants of the MCF-7 human breast cancer cell line. Breast Cancer Research and Treatment, 1983, 3, 23-32.	2.5	40
93	Presence and steroid inducibility of glutamine synthetase in human leukemic cells. The Journal of Steroid Biochemistry, 1983, 19, 1665-1670.	1.1	6
94	Glucocorticoid receptor studies in human leukemia. The Journal of Steroid Biochemistry, 1981, 15, 261-268.	1.1	16
95	Antibody to estrogen-induced protein (IP) and quantification of the protein in rat uterus by a radioimmunoassay. Biochemical and Biophysical Research Communications, 1977, 76, 1230-1237.	2.1	9
96	Induced Protein Synthesis and Oestradiol Binding to the Nuclei in the Rat Uterus. Nature: New Biology, 1973, 245, 154-155.	4.5	17